未登录

W

Wei Yin

Takeda Pharmaceutical Company Ltd

H指数:17

被引数:1,903

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trial

GPR139激动剂TAK-041对精神分裂症患者的脑血流和奖赏系统功能产生时间依赖性改变：一项随机安慰剂对照试验

Psychopharmacology

IF3.3

2025-08-160

OAAI

Concentration-QTc analysis of soticlestat in healthy adults: An alternative to a thorough QT study

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-09-231

OAAI

Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-03-062

OA

Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2023-11-124

OAAI

Clinical Characterization of [18F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2023-09-280

OAAI

Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2023-05-224

OAAI

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-04-177

OA

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET

NEUROPSYCHOPHARMACOLOGY

IF7.1

2021-10-217

OAAI

Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-07-3112

OAAI

Design, Synthesis, and Biological Evaluation of Organic Nitrite (NO2-) Donors as Potential Anticerebral Ischemia Agents

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-07-228

PREAI

Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-06-1017

OAAI

Design and synthesis of the ring-opened derivative of 3-n-butylphthalide-ferulic acid-glucose trihybrids as potential anti-ischemic agents

CHINESE CHEMICAL LETTERS

IF8.9

2020-07-0112

PREAI

Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H2S-donating moieties as a potential anti-ischemic stroke agent

发现带有NO/H2S-donating部分的3-n-丁基苯酞的开环衍生物作为潜在的抗缺血性中风剂

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2016-06-0139

PREAI

Antagonism of chemokine receptor CCR8 is ineffective in a primate model of asthma

IF7.7

2013-03-0111

OAAI

Contribution of a1 subunit-containing GABA-A receptors to diazepam-induced motor impairment

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2010-08-010

PREAI

Rapidly Increased Neuronal Mitochondrial Biogenesis After Hypoxic-Ischemic Brain Injury

IF8.9

2008-11-01224

OAAI

Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats

新生大鼠缺氧/缺血后促红细胞生成素通过血管再生和神经发生促进神经元替代

IF8.9

2007-10-01177

OAAI

Preconditioning suppresses inflammation in neonatal hypoxic ischemia via Akt activation

IF8.9

2007-03-01105

PREAI

Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2007-01-1037

PREAI

TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF

NEUROBIOLOGY OF DISEASE

IF5.6

2006-02-01105

PREAI